MolMed S.p.A. – Product Pipeline Review – Q1 2011

Document Sample
MolMed S.p.A. – Product Pipeline Review – Q1 2011 Powered By Docstoc
					    MolMed S.p.A. – Product Pipeline Review – Q1 2011
                                                                                          Reference Code: GMDHC1264CDB

                                                                                                Publication Date: JUN 2011

MolMed S.p.A. – Product Pipeline Review – Q1 2011                                           GMDHC1264CDB / Published JUN 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                Page(1)
MolMed S.p.A. – Product Pipeline Review

Ta b le o f Co n te n ts
Table of Contents                                                                                                     2
List of Tables                                                                                                        4
List of Figures                                                                                                       5
MolMed S.p.A. Snapshot                                                                                                6
    MolMed S.p.A. Overview                                                                                            6
    Key Information                                                                                                   6
    Key Facts                                                                                                         6
MolMed S.p.A. – Research and Development Overview                                                                     7
    Key Therapeutic Areas                                                                                             7
MolMed S.p.A. – Pipeline Review                                                                                      10
    Pipeline Products by Stage of Development                                                                        10
    Pipeline Products – Monotherapy                                                                                  11
    Pipeline Products – Combination Treatment Modalities                                                             12
MolMed S.p.A. – Pipeline Products Glance                                                                             13
    MolMed S.p.A. – Late Stage Pipeline                                                                              13
         Phase III Products/Combination Treatment Modalities                                                         13
    MolMed S.p.A. Clinical Stage Pipeline Products                                                                   14
         Phase II Products/Combination Treatment Modalities                                                          14
         Phase I Products/Combination Treatment Modalities                                                           15
    MolMed S.p.A.–Early Stage Pipeline Products                                                                      16
         Pre-Clinical Products/Combination Treatment Modalities                                                      16
         Discovery Products/Combination Treatment Modalities                                                         17
MolMed S.p.A. – Drug Profiles                                                                                        18
    NGR-hTNF                                                                                                         18
         Product Description                                                                                         18
         Mechanism of Action                                                                                         18
         R&D Progress                                                                                                18
    NGR-hTNF + Vinorelbine                                                                                           20
         Product Description                                                                                         20
         Mechanism of Action                                                                                         20
         R&D Progress                                                                                                20
    NGR-hTNF + Gemcitabine                                                                                           21
         Product Description                                                                                         21
         Mechanism of Action                                                                                         21
         R&D Progress                                                                                                21
    TK Cells                                                                                                         22
         Product Description                                                                                         22
         Mechanism of Action                                                                                         22
         R&D Progress                                                                                                22
    M3TK                                                                                                             23
         Product Description                                                                                         23
         Mechanism of Action                                                                                         23
         R&D Progress                                                                                                23
    NGR-hTNF                                                                                                         24
         Product Description                                                                                         24
         Mechanism of Action                                                                                         24

MolMed S.p.A. – Product Pipeline Review – Q1 2011                                         GMDHC1264CDB / Published JUN 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                             Page(2)
MolMed S.p.A. – Product Pipeline Review

         R&D Progress                                                                                                24
    NGR-hTNF + Cisplatin                                                                                             26
         Product Description                                                                                         26
         Mechanism of Action                                                                                         26
         R&D Progress                                                                                                26
    NGR-hTNF + Cisplatin + Gemcitabine                                                                               27
         Product Description                                                                                         27
         Mechanism of Action                                                                                         27
         R&D Progress                                                                                                27
    NGR-hTNF + Cisplatin + Pemetrexed                                                                                28
         Product Description                                                                                         28
         Mechanism of Action                                                                                         28
         R&D Progress                                                                                                28
    NGR-hTNF + Doxorubicin                                                                                           30
         Product Description                                                                                         30
         Mechanism of Action                                                                                         30
         R&D Progress                                                                                                30
    NGR-hTNF + Oxaliplatin + Capecitabine                                                                            31
         Product Description                                                                                         31
         Mechanism of Action                                                                                         31
         R&D Progress                                                                                                31
    NGR-hTNF                                                                                                         32
         Product Description                                                                                         32
         Mechanism of Action                                                                                         32
         R&D Progress                                                                                                32
    NGR-hTNF + Cisplatin                                                                                             34
         Product Description                                                                                         34
         Mechanism of Action                                                                                         34
         R&D Progress                                                                                                34
    NGR-hTNF + Doxorubicin                                                                                           35
         Product Description                                                                                         35
         Mechanism of Action                                                                                         35
         R&D Progress                                                                                                35
    NGR-IFN-Gamma                                                                                                    36
         Product Description                                                                                         36
         Mechanism of Action                                                                                         36
         R&D Progress                                                                                                36
    NGR-IL 12                                                                                                        37
         Product Description                                                                                         37
         Mechanism of Action                                                                                         37
         R&D Progress                                                                                                37
MolMed S.p.A. – Pipeline Analysis                                                                                    38
    MolMed S.p.A. – Pipeline Products by Therapeutic Class                                                           38
    MolMed S.p.A. - Pipeline Products By Target                                                                      39
    MolMed S.p.A. – Pipeline Products by Route of Administration                                                     41
    MolMed S.p.A. – Pipeline Products by Molecule Type                                                               42
MolMed S.p.A. – Recent Pipeline Updates                                                                              43
MolMed S.p.A. – Locations And Subsidiaries                                                                           45

MolMed S.p.A. – Product Pipeline Review – Q1 2011                                         GMDHC1264CDB / Published JUN 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                             Page(3)
MolMed S.p.A. – Product Pipeline Review

    Head Office                                                                                                      45
Financial Deals Landscape                                                                                            46
    MolMed S.p.A., Deals Summary, 2004 to 2011                                                                       46
    MolMed S.p.A. Detailed Deal Summary                                                                              47
         Takara Bio Enters Into Collaboration Agreement With MolMed                                                  47
         Licensing Agreements                                                                                        48
         Oxford BioMedica Enters Into Licensing Agreement With MolMed                                                48
Appendix                                                                                                             49
    Methodology                                                                                                      49
Description: MolMed S.p.A. – Product Pipeline Review – Q1 2011 Summary Global Market Direct’s pharmaceuticals report, “MolMed S.p.A. - Product Pipeline Review - Q1 2011” provides data on the MolMed S.p.A.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, MolMed S.p.A.’s corporate website, SEC filings, investor presentations and featured press releases, both from MolMed S.p.A. and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - MolMed S.p.A. - Brief MolMed S.p.A. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of MolMed S.p.A. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of MolMed S.p.A. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the MolMed S.p.A.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate MolMed S.p.A.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of MolMed S.p.A. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the MolMed S.p.A.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill por
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries